Navigation Links
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
Date:4/21/2008

SMIP(TM) technology to create a portfolio of product candidates with customized mechanisms of action in an effort to optimize patient safety, efficacy and convenience.

"Initiation of the SBI-087 Phase 1 clinical trial marks an important milestone in advancing our pipeline through our collaboration with Wyeth," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "We believe SBI-087 and TRU-015 together will play an important role in improving patient care and helping us establish category leadership in autoimmune and inflammatory disease markets."

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Ariz. , July 1, 2015 Prismic ... drugs and FDA-regulated medical foods, today announced the election ... A. Simonetti to its Board of Directors. ... Board members, Peter Moriarty , Chairman and CEO ... Krivulka and Martin Simonetti have accepted ...
(Date:7/1/2015)...  Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), ... commercialization of proprietary compounded drug formulations, today announced ... market closing bell on Thursday, July 2, 2015.  ... Go Dropless™ campaign since its launch in April ... annually in the U.S. and more than 4.3 ...
(Date:7/1/2015)... ExeGi Pharma, a company focused on developing ... that it has been granted a product license by ... (NNHPD) to sell Visbiome™ in Canada ... Claudio De Simone , MD, PhD and has ... Simone recently signed an exclusive agreement with ExeGi Pharma ...
Breaking Medicine Technology:Joseph Krivulka and Martin Simonetti Join Board of Prismic Pharmaceuticals 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3
... Jan. 19, 2011 On February 1, 2011, the ... Center for Biomedical Innovation, and Engineering Systems Division will ... Systems Thinking from Discovery to Delivery ... day-long event, sponsored by Merrimack Pharmaceuticals, will be a ...
... RFID Journal features MEPS Real Time,s ... live or die depending on the correct medications being ... tracking of a drug,s expiration dates, information about the ... in REAL TIME, would assist in preventing errors. ...
Cached Medicine Technology:Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 2Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 3Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 4Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 5Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 6Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 7Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium 8MEPS Real Time's New RFID Drug Management System Provides Critical Error Solution for California Hospital 2
(Date:7/1/2015)... Livonia, Mich. (PRWEB) , ... July 01, 2015 ... ... the transition of Catholic sponsorship complete, St. Joseph’s Health, located in Syracuse, N.Y., ... "With the closing today, we have gained an admirable and important partner committed ...
(Date:7/1/2015)... New York, NY (PRWEB) , ... July 01, 2015 , ... ... around which DNA is wound, histones, remain constant in the brain, never changing after ... Sinai have discovered that histones are steadily replaced in brain cells throughout life – ...
(Date:7/1/2015)... Calif. (PRWEB) , ... July 01, 2015 , ... ... orthodontic technology and services, today announced that its fifth annual Smile for a ... raised $80,000 for the non-profit organization. In addition to supporting S4L in its ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and Families (CCF) announced ... grant will allow CCF to improve quality of care and save costs for the ... respond to many changes in New York’s Medicaid system. Experts agree that children need ...
(Date:7/1/2015)... ... July 01, 2015 , ... During the first week ... Sales Training and Development) and Chuck Corso (Associate Sales Trainer) participated in the ... LTEN brings together learning and development professionals from more than 300 life sciences ...
Breaking Medicine News(10 mins):Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4
... are reporting development of a fast, simple, inexpensive method ... may cause skin allergies in people -- a method ... appears in ACS, Chemical Research in Toxicology , ... colleagues note the existence of public sentiment against the ...
... ... silicone gel-filled breast implants will have at least one broken implant within 11 ... ruptures. Smart Choice MRI has become the first MRI clinic in Milwaukee to ... screening procedure costs only $600, up to a 75% savings when compared to ...
... ... Commission approves methods to assess up to $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 ... have joined the Certificate Exchange Network (CEN) offered by the National Association of Chain ...
... statin drugs given to patients to treat heart disease should ... concludes a new study published on bmj.com . ... can lead to an increased risk of liver dysfunction, acute ... disease is a leading cause of premature death and a ...
... of Mayo Clinic Proceedings , physician ... patients. The physician experts reviewed all current literature available ... search to recommend a uniform and practical guide to ... a substantial public health problem, accounting for approximately 770,000 ...
... Dr. Steven ... muscle pain therapy called the Active Release Technique. Active Release Technique is different because ... ... office, noted local chiropractor, Dr. Steven Shoshany, has recently expanded his practice to ...
Cached Medicine News:Health News:Affordable Implant Screening: Protect Against "Silent" Ruptures 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3Health News:Some statins have unintended effects and warrant closer monitoring, study finds 2Health News:Mayo Clinic Proceedings: Review of pain management practices for cirrhosis patients 2Health News:NYC Chiropractor Expands Practice with Therapy for Muscle and Overuse Injuries 2
... Corning 7087 Large tip opening allows more rapid ... Colored graduations are enameled onto the glass. Two ... top indicate the pipet is calibrated"To Deliver"its total ... O.D. L 8 350 mm graduations ...
These reusable 0.1mL PYREX serological pipets are color coded by size for easy identification and sorting. Colored graduations are enameled onto the glass. These "to deliver" (TD) pipets must be blow...
... These precision 4mL PYREX ... calibrated "To Contain" (TC - ... (TD - top line) to ... ware. Pipets are color-coded with ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Medicine Products: